News
Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.
Kaplan Fox & Kilsheimer LLP announces that class action lawsuits have been filed against Hims & Hers Health, Inc. (“Hims & Hers” o ...
Hims & Hers Health delivered a first quarter that surpassed Wall Street’s expectations, driven by strong adoption of its ...
Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.
Our writer reveals what he thinks is the most exciting from the four investments he made in his Stocks and Shares ISA last ...
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN HIMS & HERS HEALTH, INC. (HIMS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE AUGUST 25, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING ...
Investing.com -- AI-related stocks topped trading activity on Robinhood U.K. in June, led by Nvidia (NASDAQ: NVDA ), ...
According to Regeneron, the drug is a bispecific antibody that binds to B-cell maturation antigen (BCMA) on cancerous plasma cells and CD3 on T cells, directing the immune system to attack and destroy ...
New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...
Hims & Hers' high valuation is no longer justified amid mounting execution and revenue risks. Click here to read why I ...
Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results